These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8554043)

  • 41. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.
    Gianni AM; Bregni M; Siena S; Orazi A; Stern AC; Gandola L; Bonadonna G
    J Clin Oncol; 1990 May; 8(5):768-78. PubMed ID: 2185337
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
    Sawada KI; Sato N; Kohno M; Hannda H; Yasukouchi T; Tanngo M; Hirayama A; Koike T
    Leuk Lymphoma; 1995 Dec; 20(1-2):103-9. PubMed ID: 8750630
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer.
    Hoekman K; Wagstaff J; van Groeningen CJ; Vermorken JB; Boven E; Pinedo HM
    J Natl Cancer Inst; 1991 Nov; 83(21):1546-53. PubMed ID: 1960751
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.
    Tanosaki R; Okamoto S; Akatsuka N; Ishida A; Michikawa N; Masuda Y; Uchida H; Murata M; Kizaki M; Ikeda Y
    Cancer; 1994 Oct; 74(7):1939-44. PubMed ID: 7521788
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells.
    Meisenberg B; Brehm T; Schmeckel A; Miller W; McMillan R
    Transfusion; 1998 Feb; 38(2):209-15. PubMed ID: 9531956
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer.
    Ferguson JE; Dodwell DJ; Seymour AM; Richards MA; Howell A
    Br J Cancer; 1993 Apr; 67(4):825-9. PubMed ID: 7682432
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dose-intense paclitaxel, etoposide and cyclophosphamide: a safe and active regimen for tumor cytoreduction and stem cell mobilization in metastatic breast cancer.
    Bilgrami S; Feingold JM; Bona RD; Edwards RL; Khan AM; Rodriguez-Pinero F; Khan IA; Kazierad D; Clive J; Tutschka PJ
    Bone Marrow Transplant; 2000 Jan; 25(2):123-30. PubMed ID: 10673668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Shorter interval between cycles of cyclophosphamide, doxorubicin, cisplatin using recombinant human granulocyte colony-stimulating factor for urothelial cancer--phase I/II study.
    Yoshida O; Kakehi Y; Arai Y; Tomoyoshi T; Okada Y; Matsuda T; Mikami O; Fukuyama T; Hida S; Okabe T
    Int J Urol; 1995 Nov; 2(5):316-21. PubMed ID: 8749950
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase I trial of standard and cyclophosphamide dose-escalated CHOP with granulocyte colony stimulating factor in elderly patients with non-Hodgkin's lymphoma.
    Meyer RM; Gyger M; Langley R; Lespérance B; Caplan SN
    Leuk Lymphoma; 1998 Aug; 30(5-6):591-600. PubMed ID: 9711921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life.
    Swain SM; Rowland J; Weinfurt K; Berg C; Lippman ME; Walton L; Egan E; King D; Spertus I; Honig SF
    J Clin Oncol; 1996 May; 14(5):1565-72. PubMed ID: 8622073
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
    Holmes FA
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
    J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vinorelbine and low-dose cyclophosphamide in the treatment of pediatric sarcomas: pilot study for the upcoming European Rhabdomyosarcoma Protocol.
    Casanova M; Ferrari A; Bisogno G; Merks JH; De Salvo GL; Meazza C; Tettoni K; Provenzi M; Mazzarino I; Carli M
    Cancer; 2004 Oct; 101(7):1664-71. PubMed ID: 15378498
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer.
    Kennedy MJ; Zahurak ML; Donehower RC; Noe DA; Sartorius S; Chen TL; Bowling K; Rowinsky EK
    J Clin Oncol; 1996 Mar; 14(3):783-91. PubMed ID: 8622024
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer.
    Hietanen P; Teerenhovi L; Joensuu H
    Oncology; 1999; 56(2):103-9. PubMed ID: 9949294
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cyclophosphamide, adriamycin, and cis-platinum (CAP) in metastatic and locally advanced breast cancer.
    Verusio C; Bajetta E; Ferrari L; Bartoli C; Valagussa P; Bonadonna G
    Am J Clin Oncol; 1988 Aug; 11(4):435-9. PubMed ID: 3407621
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group.
    von Minckwitz G; Raab G; Caputo A; Schütte M; Hilfrich J; Blohmer JU; Gerber B; Costa SD; Merkle E; Eidtmann H; Lampe D; Jackisch C; du Bois A; Kaufmann M
    J Clin Oncol; 2005 Apr; 23(12):2676-85. PubMed ID: 15837982
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
    Yeung AW; Pang YK; Tsang YC; Wong SW
    Cancer; 1994 Apr; 73(7):1960-70. PubMed ID: 7511042
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
    Agiro A; Ma Q; Acheson AK; Wu SJ; Patt DA; Barron JJ; Malin JL; Rosenberg A; Schilsky RL; Lyman GH
    J Clin Oncol; 2016 Nov; 34(32):3872-3879. PubMed ID: 27646945
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pilot study of adriamycin and amsacrine (m-AMSA) in patients with advanced breast cancer.
    Chang AY; Solan A; Kaplan BH; Vogl SE; Camacho FJ; Taylor SG
    Am J Clin Oncol; 1988 Oct; 11(5):535-7. PubMed ID: 3177254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.